Business
Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope
— Rigorous testing demonstrates robust antimicrobial performance against bacterial strains relevant to cardiac implanted electronic device (CIED) infections — SILVER SPRING, Md., March 25, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of new preclinical data in the current issue of Antibiotics, further demonstrating the antimicrobial performance of its antibiotic-eluting biologic
About this update from Elutia, Inc.
[{"type":"image","alt":"Elutia Inc.","displaySize":"","headline":null,"caption":"Elutia Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":67,"url":"https://media.zenfs.com/en/globenewswire.com/a29e66fb8a73dd1618af733c91ecea76"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/c1mHLTLmof012jV7WnpAyg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a29e66fb8a73dd1618af733c91ecea76","width":300,"height":67}},"lazy":false},{"type":"text","content":"— Rigorous testing demonstrates robust antimicrobial performance against bacterial strains relevant to cardiac implanted electronic device (CIED) infections — ","length":158,"tagName":"p"},{"type":"text","content":"SILVER SPRING, Md., March 25, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of new preclinical data in the current issue of Antibiotics, further demonstrating the antimicrobial performance of its antibiotic-eluting biologic envelope designed to protect CIEDs from bacterial infections.","length":402,"tagName":"p"},{"type":"text","content":"“These findings highlight the antibiotic-eluting bioenvelope as a comprehensive approach to protecting against bacterial strains associated with CIED infections,” said Dr. M. Rizwan Sohail, Professor of Medicine at Baylor College of Medicine and an author on the publication. “The study demonstrated complete eradication of bacteria even with only a fraction of the drug remaining, in a soft, conforming bioenvelope for overall device protection.”","length":447,"tagName":"p"},{"type":"text","content":"The study utilized an innovative approach to correlate in vivo and in vitro results, establishing a new tool for assessing the antimicrobial effectiveness of implantable biomaterials. Data showed rapid initial elution of antibiotics followed by more gradual elution over 14 days. Broad spectrum activity was shown across seven different Gram positive and Gram negative organisms, including Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA), and Staphylococcus epidermidis, with complete eradication of all tested strains. This study serves as a companion to the seminal Garrigos study published in 2024, which showed antimicrobial performance in a challengin...